Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Medicare Unlikely To Embrace Cost Effectiveness In Early Price Negotiations – ICER’s Pearson

Executive Summary

The government’s rush to stand up the negotiation program by the fall likely means an approach to cost effectiveness will be left out of at least the first cycle. But it could be incorporated over time.

You may also be interested in...

Medicaid Use Of QALYs As Basis Of Drug Coverage Restrictions Would Be Barred By HHS Proposal

Prohibition by Health and Human Services Department Office of Civil Rights would apply to use of such metrics in determining formulary access but not to use in ‘academic’ research.

Outgoing PhRMA Exec: Industry Needs To Better Tell Its Innovation Story

The brand drug industry’s success in tackling COVID-19 followed by swift political loss with the Inflation Reduction Act is in part due to the public’s continued knowledge gaps about the medical innovation ecosystem, outgoing PhRMA VP Jenny Bryant tells Pink Sheet in an interview.

ICER Hands CMS A Drug Price Negotiation Cheat Sheet On Eliquis, Xarelto

Drug price assessment group ran cost analyses on two of the first 10 drugs selected for Medicare price negotiations, Eliquis and Xarelto, and submitted the report to the US government.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts